Frontiers in Oncology (Feb 2021)
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
- Johannes Sam,
- Sara Colombetti,
- Tanja Fauti,
- Andreas Roller,
- Marlene Biehl,
- Linda Fahrni,
- Valeria Nicolini,
- Mario Perro,
- Tapan Nayak,
- Esther Bommer,
- Anne Schoenle,
- Maria Karagianni,
- Marine Le Clech,
- Nathalie Steinhoff,
- Christian Klein,
- Pablo Umaña,
- Marina Bacac
Affiliations
- Johannes Sam
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Sara Colombetti
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Tanja Fauti
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Andreas Roller
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
- Marlene Biehl
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Linda Fahrni
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Valeria Nicolini
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Mario Perro
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Tapan Nayak
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
- Esther Bommer
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Anne Schoenle
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Maria Karagianni
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Marine Le Clech
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Nathalie Steinhoff
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Christian Klein
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Pablo Umaña
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- Marina Bacac
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
- DOI
- https://doi.org/10.3389/fonc.2021.650149
- Journal volume & issue
-
Vol. 11
Abstract
No abstracts available.Keywords
- solid tumors
- immunotherapy
- T-cell bispecific antibody
- carcinoembryonic antigen T-cell bispecific antibody
- programmed death–ligand 1
- combination
